Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T‐cell and B‐cell lymphoproliferative disorders. (22nd November 2017)

• Record Type: Journal Article
• Authors: Comfere, Nneka; Sundram, Uma; Hurley, Maria Yadira; Swick, Brian
• Is Part Of: Journal of cutaneous pathology. Volume 45:Number 1(2018)
• Page Start: 39
• Page End: 47
• Publication Date: 2017-11-22
• Subjects: clonality -- cutaneous lymphoma -- opinions -- PCR -- practice; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.13072
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract : Background: Appropriate use criteria have been developed for many tests using expert judgment, evidence‐based practice and clinical experience. In this context, we report the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected. Methods: An Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). We conducted, summarized and presented a relevant literature search to an audience of 144 dermatopathologists with a variety of practice experiences at the 53rd Annual Meeting of the ASDP in Chicago, IL. Results: Twenty‐seven clinical scenarios for LPDs (13 T‐cell and 14 B‐cell) were defined. Forty relevant studies for T‐cell receptor gene clonality assays and 20 relevant studies for IgH/IgK clonality assays were identified. Audience response data from participating dermatopathologists reflected a wide variety of approaches to the application of clonality assays in the evaluation of LPDs, based on practice setting, personal experience and test availability. Conclusions: Our clinical scenario analysis and literature review revealed well‐supported clinical scenarios and identified opportunities for additional research to further define the utility of clonality assays in some clinical scenarios.